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Background: Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in
clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.
Methods: Three investigators retrospectively reviewed subjects enrolled in the Sildenafil Trial of Exercise
Performance in IPF who experienced a respiratory serious adverse event during the course of the study. Events
were classified as definite acute exacerbation, suspected acute exacerbation, or other, according to established
criteria.
Results: Thirty-five events were identified. Four were classified as definite acute exacerbation, fourteen as suspected
acute exacerbation, and seventeen as other. Definite and suspected acute exacerbations were clinically
indistinguishable. Both were most common in the winter and spring months and were associated with a high risk
of disease progression and short-term mortality.
Conclusions: In this study one half of respiratory serious adverse events were attributed to definite or suspected
acute exacerbations. Suspected acute exacerbations are clinically indistinguishable from definite acute exacerbations
and represent clinically meaningful events. Clinical trialists should consider capturing both definite and suspected
acute exacerbations as outcome measures.
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Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, fibrotic lung disease with a median survival of ap-
proximately 3 years [1]. The natural history of disease is
unpredictable, with many patients experiencing periods
of relative stability punctuated by episodes of acute
worsening [2,3]. Many of these acute worsenings are of
unknown cause despite careful clinical evaluation. Idio-
pathic acute worsenings are called acute exacerbations
of IPF and are associated with substantial morbidity and
mortality [4]. Because of its clinical significance, acute
exacerbation of IPF has become a key endpoint in
clinical trials of novel drug agents for IPF.* Correspondence: hal.collard@ucsf.edu
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reproduction in any medium, provided the orEpidemiological data suggest an annual incidence per
patient year of acute worsening in IPF of approximately
0.23, with acute exacerbation of IPF constituting slightly
over half of acute worsening events [5]. However, inci-
dence rates for acute exacerbation reported in recent
clinical trial populations have been substantially lower
[6-8]. The reason for this discrepancy is unknown.
Acute exacerbation of IPF is defined by strict clinical cri-
teria, which require an acute onset of symptoms, new
high-resolution computed tomography (HRCT) scan find-
ings, and no evidence of infection or other identifiable
cause [4]. Cases that are of unknown cause but do not ful-
fill the criteria listed due to missing data have been termed
suspected acute exacerbations [4] Suspected acute exacer-
bations have generally been discounted in clinical studies,
and the clinical features and behavior of this population
are unknown.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tients with IPF enrolled in the Sildenafil Trial of Exercise
Performance in IPF (STEP-IPF) to examine the inci-
dence and clinical characteristics of suspected acute
exacerbations of IPF. We find that suspected acute exac-
erbations are common in this clinical trial population
and represent clinically important outcomes.
Methods
Subjects included in this study were participants in the
Sildenafil Trial of Exercise Performance in IPF (STEP-IPF)
trial conducted by the IPF Clinical Research Network
(IPFnet) [9]. Briefly, patients were eligible for enrollment
in STEP-IPF if they met consensus criteria for the diagno-
sis of IPF [10] and had a diffusion capacity for carbon
monoxide (DLCO) of less than 35% of the predicted value.
Enrolled subjects were randomized to active drug (sildenafil
20 mg three times daily) or placebo for the first 12 weeks
of the study, then given open label sildenafil for the sec-
ond 12 weeks (Additional file 1: Figure E1). All STEP-
IPF subjects provided informed consent for the use of
their data in subsequent data analyses and were in-
cluded in this analysis.
Subjects in STEP-IPF who experienced a respiratory
serious adverse event during the course of the study (as
determined by the site principal investigator) were con-
sidered acute respiratory worsenings for the purposes of
the current study. As part of the STEP-IPF trial, possible
acute exacerbation events were pre-specified as serious
acute events and study sites were asked to collect de-
tailed information about these events from the treating
physician (not always at the study site). STEP-IPF did
not identify definite and suspected acute exacerbation as
specified by the IPFnet investigators in a perspective
piece published after STEP-IPF was designed [4], so the
original STEP-IPF adjudication results for acute exacer-
bation were not used in this analysis. All acute respira-
tory worsenings were reviewed independently by three
of the authors (HC, CG, LR) and categorized as definite
acute exacerbation suspected acute exacerbation, or
other acute worsening [4]. Briefly, acute exacerbation
was defined by acute onset of symptoms (<30 days in
duration), new radiographic abnormalities (bilateral ground
glass or consolidation on HRCT), and the absence of an
identified infectious or alternative etiology (Additional
file 2: Table E1). Suspected acute exacerbation of IPF
was defined as an idiopathic acute respiratory worsen-
ing that could not be classified as a definite acute ex-
acerbation due to missing data or criteria [4]. In cases
considered as other acute worsenings, a cause was spe-
cified were possible (e.g. lower respiratory tract infec-
tion, pulmonary embolism). After individual reviews, all
events were discussed as a group, and in cases of dis-
agreement, a consensus result for each was determined.Inter-rater reliability for definite acute exacerbation and
definite/suspected acute exacerbation was determined for
the three reviewers by calculating single kappa statistics.
Comparisons between cases and selected controls were
performed using the two-sample t-test or Wilcoxon rank
sum and results were reported as mean (standard devi-
ation), median (25th, 75th), or number (percent). Incidence
rates per patient-year were determined for selected acute
worsening subgroups (e.g. definite acute exacerbation,
suspected acute exacerbation). Chi-square tests were used
to determine the concordance of definite and suspected
acute exacerbation with other measures of disease
progression: change in forced vital capacity (FVC, defined
as ≥10% relative decline), DLCO (defined as ≥15% relative
decline), 6 minute walk distance (6MWD, defined as ≥30
meter decline), University of California San Diego Short-
ness of Breath Questionnaire (UCSD SOBQ, defined as
≥5 point increase) and St. George’s Respiratory Ques-
tionnaire (SGRQ, defined as ≥5 point increase). In
events with missing data due to death, disease progres-
sion was considered to have occurred by the above
variables. Survival analysis was performed using
Kaplan-Meier survival estimates from the documented
date of the acute worsening event. In some instances,
definite acute exacerbation of IPF and suspected acute
exacerbation of IPF events were combined into a single
“acute exacerbation of IPF” group to enable statistical
comparisons. All statistical analysis was performed
using SAS Version 9.
Results
Cohort description
One hundred and eighty subjects constituted the study co-
hort. Thirty-five respiratory serious adverse events oc-
curred during the course of the study; 31 of these were
associated with hospitalization. Of these, eighteen (51%)
were considered definite (four) or suspected (fourteen)
acute exacerbation of IPF (Figure 1). Ten of the eleven ori-
ginal cases of acute exacerbation of IPF in the STEP-IPF
study adjudicated per protocol and reported in the original
manuscript were included in this group; the eleventh case
was reclassified as other acute worsening. All but one of
the fourteen suspected acute exacerbation cases were so
classified because they did not undergo HRCT and/or re-
spiratory culture; four were missing only evaluation for in-
fection (Additional file 2: Table E2). High resolution
computed tomography and respiratory culture were not
required by the study protocol and were not routinely
performed by treating physicians.
Inter-rater reliability for the adjudication of events as def-
inite acute exacerbation of IPF (i.e. definite acute exacerba-
tion versus suspected acute exacerbation, other or
insufficient data) was good (0.72, 95% confidence interval
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Figure 1 Incidence of acute respiratory worsening by cause. The adjudicated cause of the 35 acute respiratory worsening events in the
STEP-IPF cohort are represented. Four definite acute exacerbations (black bar) and fourteen suspected acute exacerbations (striped bar) were
identified. Cases of other acute worsenings are listed by cause (grey bars). Abbreviations: AEX = acute exacerbation; LTR = lower respiratory tract.
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these, three cases were unanimous (all three reviewers
called them definite), five were classified as definite or
suspected acute exacerbation, and one was classified as
definite acute exacerbation, suspected acute exacerbation,
and insufficient data available to adjudicate. The inter-rater
reliability for definite or suspected acute exacerbation ver-
sus other or insufficient data was fair (0.43, 95% confidence
interval 0.26 to 0.60).Figure 2 Seasonal variation in risk of definite and suspected acute ex
events (definite acute exacerbation = black; suspected acute exacerbation
month. The number of acute exacerbation events (definite and suspected)
significantly higher from December to May than from June to November, wIncidence and characteristics of acute exacerbation
The overall incidence per patient year of acute wors-
ening of any cause was 0.39 (CI 0.31, 0.60). The inci-
dence of definite acute exacerbation of IPF was 0.04
(CI 0.01, 0.12) and of suspected acute exacerbation
was 0.16 (CI 0.09, 0.26). There was a strong seasonal
association, with an odds ratio of 8.06 (CI 1.76,
36.89, p = 0.007) for definite or suspected acute ex-
acerbation of IPF occurring from December throughacerbation and acute worsening. The number of acute worsening
= striped; other acute worsening = grey) are demonstrated by calendar
per month normalized to the number of patients at risk were
ith an odds ratio of 8.06 (95% CI 1.76, 36.89, p = 0.007).
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This association was also true for other acute wors-
enings. This finding was not explained by differences
in the number of patients at risk during those
months.
Subjects with definite or suspected acute exacerba-
tion of IPF reported increased dyspnea (94%) and
cough (88%). Symptoms of infection such as fever
and congestion were reported in the minority (31%
and 24%, respectively). Over half of these subjects
developed respiratory failure requiring non-invasive
ventilation (18%) or intubation (35%). Most subjects
received corticosteroids (81%) and antibiotic therapy
(88%) as part of their treatment. Characteristics of
definite and suspected acute exacerbations were iden-
tical, but the number of cases was too small in these
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Sildenafil use ** 8 (47%) 5 (39%) 76 (51%)
PPI use 3 (18%) 7 (54%) 68 (45%)
Prednisone
use
7 (41%) 2 (15%) 28 (19%)
* Combined definite and suspected cases.
** Subjects randomized to active therapy during the first 12 weeks of STEP-IPF.Predictors of acute exacerbation and acute worsening
Subjects with definite or suspected acute exacerbation of
IPF had worse dyspnea score (UCSD SOBQ), worse pul-
monary physiology (FVC and DLCO), worse 6MWD,
and worse oxygenation at baseline compared to subjects
without acute worsening (Table 1). There was also an in-
creased prevalence of patient reported coronary artery
disease compared to subjects without acute worsening
(53% vs. 25%, p = 0.02). Subjects who developed definite
or suspected acute exacerbation of IPF had significantly
greater baseline prednisone use (41% vs. 19%, p = 0.05)
and a trend towards lesser baseline PPI use (18% vs. 45%,
p = 0.09). There was no significant difference between
groups in study arm (active sildenafil vs. placebo), age, or
history of cigarette smoking. Subjects with other acute
worsenings appeared similar to the acute exacerbation
subjects, and risk factors for acute worsening of anyorsening status
50
Acute exacerbation vs. No
acute worsening P-value
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exacerbation.
Prognostic significance of acute exacerbation and acute
worsening
Definite or suspected acute exacerbation of IPF was associ-
ated with progression of disease as defined by categorical
change in FVC, DLCO, 6MWD, UCSD SOBQ, and SGRQ
(Figure 3). Findings were similar for subjects with other
acute worsenings. There were fifteen deaths overall in the
study cohort; eight (53%) occurred in the definite (n = 2) or
suspected (n = 6) acute exacerbation of IPF group; six
occurred in the other acute worsening group. Only one
occurred in subjects without acute worsening. Overall
24-week mortality in the definite or suspected acute ex-
acerbation of IPF group was 47%, similar to that of subjects
with other acute worsenings (Table 2). This was signifi-
cantly greater that the 24-week mortality in subjects with-
out acute worsening (1%, p < 0.01). Most deaths in the
definite or suspected acute exacerbation of IPF and other
acute worsening group occurred within twelve weeks of
the acute exacerbation event (Figure 4).
Discussion
These results suggest that suspected acute exacerbations of
IPF are common, clinically relevant events in patients en-
rolled in clinical trials of IPF. The similar clinical character-
istics, risk factors, and clinical outcomes of definite and
suspected acute exacerbation cases suggest that suspected
acute exacerbations may, in many cases, represent trueFigure 3 Association of acute exacerbation and other acute worsenin
defined by ≥10% relative decline in forced vital capacity (FVC), ≥ 15% relati
meter decline in 6 minute walk distance (6MWD), ≥ 5 point increase in the
questionnaire, and ≥ 5 point increase in the St. George’s Respiratory Questiacute exacerbation of IPF. Based on these observations, we
believe that suspected acute exacerbations should be cap-
tured and analyzed as a clinical trial endpoint.
Very few definite acute exacerbations of IPF were
identified in this study, consistent with recent clinical
trial results [6-8]. We hypothesize that the adoption of
strict criteria for acute exacerbation of IPF and logis-
tical limitations in the clinical trial setting (e.g. diffi-
culty obtaining clinical reports from outside hospitals,
adjudicating cases based only on written reports) has
resulted in the under-recognition of actual acute
exacerbation events. The reclassification of 6 acute ex-
acerbations from the original STEP-IPF trial as
suspected acute exacerbations in this reanalysis using
the current, stricter criteria for acute exacerbation il-
lustrates this point. We believe these “missed” acute
exacerbations are captured by the suspected acute ex-
acerbation endpoint. Interestingly, combining definite
and suspected acute exacerbations in this STEP-IPF
re-analysis results in an incidence of 0.20 per patient
year, similar to what has been described in a recent
large epidemiological study [5]. This is unlikely to be
the only reason for the low number of definite acute
exacerbations identified in this and other clinical trials
(e.g. improved clinical care for subjects enrolled in
trials could contribute), but the possibility of a meth-
odological contribution should be explored further in
future clinical trials.
Disease severity and ethnicity have been suggested as
potential reasons for varying rates of acute exacerbationgs with disease progression. Disease progression was variably
ve decline in diffusion capacity for carbon monoxide (DLCO), ≥ 30
University of California San Diego (UCSD) shortness of breath
onnaire (SGRQ).
Table 2 24-week mortality by acute worsening status
Group Number of deaths Number at risk 24-week mortality
Acute Exacerbation of IPF * 8 17 47%
Other Acute Worsening 6 13 46%
No Acute Worsening 1 150 1%
* Combined definite and suspected cases. Two deaths were in the definite acute exacerbation group (50% mortality rate at 24 weeks) and six deaths were in the
suspected acute exacerbation group (46% mortality rate at 24 weeks).
Abbreviations: IPF, idiopathic pulmonary fibrosis.
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multiple measures of disease severity are associated with
increased risk of definite and suspected acute exacerba-
tion suggests that patients with earlier disease (i.e. those
patients typically enrolled into clinical trials of novel
drug agents) may have a lower incidence than the gen-
eral population of IPF patients and the more advanced
population enrolled into STEP-IPF. However, there are
plausible explanations for why acute exacerbation ap-
pears to occur more frequently in patients with ad-
vanced disease that have nothing to do with the actual
rate of events (e.g. decreased physiologic reserve in ad-
vanced disease resulting in more clinical signs and
symptoms, increased health care utilization in advanced
disease resulting in a greater chance of clinical recogni-
tion). Ethnic and racial differences in acute exacerbation
risk may also exist, although data from recent clinical
trials conducted in the United States, Europe and Japan
using similar criteria for acute exacerbation adjudication
do not support this hypothesis [6,7,11-13].
We believe a strong argument can be made for includ-
ing both definite and suspected acute exacerbations
as outcome measures in clinical trials. First, suspected
acute exacerbations of IPF are clearly common, clinically
important events. Second, our data support the hypoth-
esis that many suspected acute exacerbations are indeedFigure 4 Acute worsening and survival. Cases adjudicated as
definite or suspected acute exacerbation (AEX) of IPF (solid line) and
other acute worsening (dashed line) were associated with similar
short-term risk of death.acute exacerbations. Third, in many clinical centers,
HRCT scanning and respiratory cultures are not rou-
tinely performed on IPF patients with idiopathic respira-
tory worsening, as the tests are not felt to change
clinical management (patients are simply treated empir-
ically for both pneumonia and acute exacerbation), and
involve cost and risk. These cases, therefore, cannot be
classified as definite acute exacerbations. For all of these
reasons, we believe that including suspected acute exac-
erbations along with definite acute exacerbations as end-
points in clinical trials will most appropriately capture
the clinically meaningful events of interest to clinical
trialists. Whether definite and suspected acute exacerba-
tions should in fact be combined into a single endpoint
in clinical trials remains unclear.
The association of season with both definite and
suspected acute exacerbation of IPF is notable, and sug-
gests that there may be factors such as respiratory viral
infection or air pollution (products of combustion, par-
ticulate matter) that contribute to the pathogenesis of
these events. This seasonal association has not been reli-
ably demonstrated in retrospective cohort studies [5,14],
and it has been difficult to demonstrate widespread evi-
dence of infection in cohorts of carefully evaluated cases
[5,15,16]. However, this finding is striking and suggests
that seasonal risk factors may play a role in acute exacer-
bation of IPF.
Conclusion
In summary, we report that suspected acute exacerba-
tions of IPF are common in the clinical trial setting, are
clinically indistinguishable from definite acute exacerba-
tions, and are associated with a similarly high risk of dis-
ease progression and short-term mortality. There should
be no doubt that suspected acute exacerbation of IPF is
a clinically important event in the lives of patients. We
propose that those responsible for designing future clin-
ical trials rethink the methodological approach to cap-
turing acute exacerbation of IPF, and consider less
restrictive criteria. Specifically, we propose recording
both definite and suspected acute exacerbations of IPF,
and analyzing them either as separate outcome measures
or as a combined idiopathic acute worsening endpoint.
Additional changes to the methodology of acute exacer-
bation identification in clinical trials may also be
Collard et al. Respiratory Research 2013, 14:73 Page 7 of 7
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process vs. central adjudication), and studies comparing
the appropriateness and feasibility of various approaches
to defining and identifying acute exacerbation of IPF in
clinical trials are greatly needed.
Additional files
Additional file 1: Figure E1. Study design for STEP-IPF. Patients were
eligible for enrollment in STEP-IPF if they met consensus criteria for the
diagnosis of IPF and had a diffusion capacity for carbon monoxide
(DLCO) of less than 35% of the predicted value. Enrolled subjects were
randomized to active drug (sildenafil 20 mg three times daily) or placebo
for the first 12 weeks of the study, then given open label sildenafil for the
second 12 weeks.
Additional file 2: Table E1. Diagnostic Criteria for Acute Exacerbation.
Table E2. Reasons for “suspected acute exacerbation” diagnosis.
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